Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer is a research paper published in Clinical Lung Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 22 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: R37CA218707
National Institutes of Health
Grant: 5R37CA218707-07
Unmet needs for specific subsets of EGFR mutated lung cancer
National Institutes of Health
Grant: 5R37CA218707-03
Unmet needs for specific subsets of EGFR mutated lung cancer
International Association for the Study of Lung Cancer
National Institutes of Health
FWCI
0.99
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals